


FORM PTO-1449

LIST OF DISCLOSURES CITED BY APPLICANT
(Use several sheets if necessary)



Atty Docket No.
P1748R1

Serial No.
09/692,504

Applicant
DeSavage, F. et al.

Filing Date
18 Oct 2000

Group
1642 1644

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
JHR	✓	1	4,275,149	23.06.81	Litman et al.		
	✓	2	4,816,567	28.03.89	Cabilly et al.		
	✓	3	5,223,409	29.06.93	Ladner et al.		
	✓	4	5,403,484	04.04.95	Ladner et al.		
	✓	5	5,545,806	13.08.96	Lonberg et al.		
	✓	6	5,545,807	13.08.96	Surani et al.		
	✓	7	5,569,825	29.10.96	Lonberg et al.		
	✓	8	5,571,698	05.11.96	Ladner et al.		
	✓	9	5,625,126	29.04.97	Lonberg et al.		
	✓	10	5,633,425	27.05.97	Lonberg et al.		
	✓	11	5,658,570	19.08.97	Newman et al.		
	✓	12	5,681,722	28.10.97	Newman et al.		
	✓	13	5,693,780	02.12.97	Newman et al.		
	✓	14	5,750,105	12.05.98	Newman et al.		
	✓	15	5,750,373	12.05.98	Garrard et al.		
JHR	✓	16	5,756,096	26.05.98	Newman et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
JHR	✓	17	WO 97/44455	27.11.97	PCT		

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

JHR	✓	18	Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs" <u>Nucleic Acids Research</u> 25:3389-3402 (1997)				
	✓	19	Bazan, J., "Structural Design and Molecular Evolution of a Cytokine Receptor Superfamily" <u>Proc. Natl. Acad. Sci. USA</u> 87:6934-6938 (1990)				
	✓	20	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991)				
	✓	21	Bolton, C., "Recent advances in the pharmacological control of experimental allergic encephalomyelitis (EAE) and the implications for multiple sclerosis treatment" <u>Multiple Sclerosis</u> 1:143 (1995)				
	✓	22	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (1985)				
	✓	23	Chambers and Allison, "Co-stimulation in T cell responses" <u>Current Opinion in Immunology</u> 9(3):396-404 (Jun 1997)				
	✓	24	Clackson et al., "Making antibody fragments using phage display libraries" <u>Nature</u> 352:624-628 (1991)				
JHR	✓	25	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York:Alan R. Liss, Inc. pps. 77-96 (1985)				

Examiner

J. Roach

Date Considered

5/23/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1748R1

Serial No.

09/692,504

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

DeSavage, F. et al.

Filing Date

18 Oct 2000

Group

1642 (G-14)

OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)

26	Cosman, D., "The Hematopoietin Receptor Superfamily" <u>Cytokine</u> 5(2):95-106 (Mar 1993)
27	Finn and Lotze, "Introduction: Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer" <u>Journal of Immunotherapy</u> 21(2):114-118 (Mar 1998)
28	Fishwild et al., "High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice" <u>Nature Biotechnology</u> 14(7):845-851 (Jul 1996)
29	Heid et al., "Real time quantitative PCR" <u>Genome Research</u> 6(10):986-994 (1996)
30	Hoogenboom and Winter, "By-passing immunisation: human antibodies from synthetic repertoires of germline V _H gene segments rearranged in vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)
31	Hsieh, C.S. et al., "Development of Th1 CD4 ⁺ T Cells Through IL-12 Produced by Listeria-Induced Macrophages" <u>Science</u> 260:547-549 (1993)
32	Jenkins, M., "The ups and downs of T cell costimulation" <u>Immunity</u> 1(6):443-446 (Sep 1994)
33	Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)
34	June et al., "The B7 and CD28 receptor families" <u>Immunology Today</u> 15(7):321-331 (Jul 1994)
35	Kaplan, M. H. et al., "Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice" <u>Nature</u> 382:174-177 (1996)
36	Kohler and Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)
37	Kuhn, R. et al., "Generation and analysis of interleukin-4 deficient mice" <u>Science</u> 254:707-710 (1991)
38	Kwon et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer" <u>Proc. Natl. Acad. Sci. USA</u> 94(15):8099-8103 (Jul 22, 1997)
39	Le Gros, G. et al., "Generation of Interleukin 4 (IL-4)-producing Cells In Vivo and In Vitro: IL-2 and IL-4 Are Required For In Vivo Generation of IL-4-producing Cells" <u>Journal of Experimental Medicine</u> 172:921-929 (1990)
40	Linsey and Ledbetter, "The Role of the CD28 receptor during T cell responses to antigen" <u>Annu. Rev. Immunol.</u> 11:191-212 (1993)
41	Lonberg and Huszar, "Human antibodies from transgenic mice" <u>International Reviews of Immunology</u> 13(1):65-93 (1995)
42	Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications" <u>Nature</u> 368(6474):856-859 (Apr 28, 1994)
43	Lynch et al., "Flt3 ligand induces tumor regression and antitumor immune responses in vivo" <u>Nature Medicine</u> 3(6):625-631 (Jun 1997)
44	Magram, J. et al., "IL-12-deficient mice are defective in IFN γ production and type 1 cytokine responses" <u>Immunity</u> 4:471-481 (1996)
45	Marks et al., "By-passing immunization: building high affinity human antibodies by chain shuffling" <u>Bio/Technology</u> 10:779-783 (1992)

Examiner

Date Considered

J. Roar

5/23/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1748R1

Serial No.

09/692,504

Applicant

DeSavauge, F. et al.

Filing Date


18 Oct 2000

Group

1642 1644

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)



OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

46	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
47	Melero et al., "Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors" <u>Nature Medicine</u> 3(6):682-685 (Jun 1997)
48	Morrison, S., "Immunology: Success in specification" <u>Nature</u> 368(6474):812-813 (Apr 28, 1994)
49	Neuberger, M., "Generating high-avidity human Mabs in mice" <u>Nature Biotechnology</u> 14(7):826 (Jul 1996)
50	Noben-Trauth, N. et al., "An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice" <u>Proc. Natl. Acad. Sci. USA</u> 94:10838-10843 (1997)
51	O'Garra, A., "Cytokines induce the development of functionally heterogeneous T helper cell subsets" <u>Immunity</u> 8:275-283 (1998)
52	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)
53	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)
54	Schwartz, R., "Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy" <u>Cell</u> 71(7):1065-1068 (Dec 24, 1992)
55	Seder, R.A. et al., "Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming" <u>Proc. Natl. Acad. Sci. USA</u> 90:10188-10192 (1993)
56	Shimoda, K. et al., "Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene" <u>Nature</u> 380:630-633 (1996)
57	Sprecher et al., "Cloning and Characterization of a Novel Class 1 Cytokine Receptor" <u>Biochem. & Biophys. Res. Comm.</u> 246:82-90 (1998)
58	Swain et al., "Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development" <u>Immunol. Rev.</u> 123:115-144 (1991)
59	Thimmappaya et al., "Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection" <u>Cell</u> 31(3 Pt 2):543-551 (Dec 1982)
60	Umetsu and DeKruyff, "Th1 and Th2 CD4+ Cells in the Pathogenesis of Allergic Diseases" <u>Soc. Exp. Biol. Med.</u> 215:11-20 (1997)
61	Urdal, D.L., "Cytokine Receptors" <u>Ann. Reports Med. Chem.</u> , Chapter 23, 26:221-228 (1991)
62	Wells et al., "Cassette Mutagenesis: an Efficient Method for Generation of Multiple Mutations at Defined Sites" <u>Gene</u> 34(2-3):315-323 (1985)
63	Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" <u>Philos. Trans. R. Soc. London Ser A</u> 317:415-423 (1986)
64	Wu, C. et al., "Characterization of IL-12 receptor β 1 chain (IL-12R β 1)-deficient mice" <u>J. Immunol.</u> 159:1658-1665 (1997)
65	Zoller and Smith, "Oligonucleotide-directed Mutagenesis Using M13-derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" <u>Nucl. Acids Res.</u> 10(20):6487-6500 (1982)

Examiner

Date Considered

5/23/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

